Key result
Among patients initiating ACEI therapy, angioedema was associated with age >65 years, history of allergy, and use of antihistamines.
Why the study?
What are the clinical determinants of angioedema and intolerance in patients initiating ACE inhibitor therapy?
Case-Control (n=276,977)
What are the clinical determinants of angioedema and intolerance in patients initiating ACE inhibitor therapy?
Answers are grounded in this paper and cite their sources.
In a large real-world primary care cohort, ACE inhibitor-induced angioedema and intolerance were significantly associated with older age, history of allergy, and the use of certain medications such as antihistamines and corticosteroids.
AIM: The aim of the present study was to describe the occurrence and determinants of angiotensin-converting enzyme (ACE) inhibitor (ACEI) intolerance and angioedema (AE) among patients initiating ACEI therapy in a real-world primary care population. METHODS: Two nested case-control studies were conducted in a cohort of 276 977 patients aged ≥45 years initiating ACEIs from 2007 to 2014 in the UK Clinical Practice Research Datalink (CPRD). Cases of AE occurring for the first time during ACEI therapy (n = 416) were matched with AE-free controls (n = 4335) on the duration of ACEI treatment. Documented switches to angiotensin-II receptor blockers in the prescription records were used to identify ACEI-intolerance cases (n = 24 709), and these were matched with continuous ACEI users (n = 84 238) on the duration of ACEI therapy. Conditional logistic regression was used to assess the associations of demographic factors, comorbidities and comedication with AE and ACEI intolerance. RESULTS: AE during ACEI therapy was associated with age over 65 years [odds ratio (OR) 1.36, 95% confidence interval (CI) 1.07, 1.73], history of allergy (OR 1.53, 95% CI 1.19, 1.96), use of calcium channel blockers (OR 1.57, 95% CI 1.23; 2.01), use of antihistamines (OR 21.25, 95% CI 16.44, 27.46) and use of systemic corticosteroids (OR 4.52, 95% CI 3.26, 6.27). ACEI intolerance was significantly associated with more comorbidities and comedication compared with AE, including allergy (OR 2.02, 95% CI 1.96, 2.09), use of antiasthmatic drugs (OR 1.51, 95% CI 1.42, 1.61) and use of antihistamines (OR 1.53, 95% CI 1.43, 1.63). CONCLUSIONS: Among ACEI users developing AE or ACEI intolerance, several comorbidities and comedication classes were significantly more prevalent compared with ACEI users not developing these adverse reactions.
No takes yet. Share an insight, caveat, or question.
Mahmoudpour et al. (2016) conducted a case-control in ACE inhibitor intolerance and angioedema (n=276,977). Risk factors including age >65 years, history of allergy, and comedications vs. Absence of these risk factors was evaluated on Angioedema during ACEI therapy associated with age over 65 years (OR 1.36, 95% CI 1.07-1.73). Among patients initiating ACEI therapy, angioedema was associated with age >65 years, history of allergy, and use of antihistamines.
Synapse has enriched 10 related papers. Consider them for comparative context: